chitosan has been researched along with Liver Dysfunction in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Alterovitz, G; Bai, Y; Bi, Y; Chen, H; Chen, X; Dai, H; Durrani, TS; Farooqi, A; Fatibello-Filho, O; Gao, L; Gong, L; Greenwell, K; Guo, YX; Han, D; He, L; Howells, L; Huang, H; Huang, S; Jester, N; Jiang, PP; Kang, P; Kang, Y; Kraemer, R; Lan, X; Lawton, S; Li, C; Li, H; Liu, G; Liu, J; Liu, P; Matthys, H; Meng, Y; Moraes, FC; Muller, I; Pan, C; Qu, L; Roberts, A; Santer, M; Silva, LP; Silva, TA; Sivyer, K; Smith, HJ; Song, F; Steele, M; Sun, N; Teasdale, E; Tong, Y; Wang, D; Wang, L; Wang, Q; Wang, S; Xiao, M; Xin, D; Xu, C; Xu, J; Yang, XL; Zhang, B; Zhang, D; Zhang, J; Zhang, L; Zhang, Q; Zhong, L; Zhu, H | 1 |
| El-Shorbagy, HM; Saleh, H | 1 |
| El-Shetry, ES; Hamed Arisha, A; Khater, SI; Metwally, MMM; Mohamed, AA; Mostafa-Hedeab, G | 1 |
| Bai, Y; Cheng, Z; Du, X; Jiang, Z; Kong, D; Li, S; Li, W; Wang, H; Wang, L; Wu, L; Yan, H; Zhu, M | 1 |
| Paulose, CS; Shilpa, J | 1 |
| Ajayan, MS; Anju, TR; Paulose, CS; Shilpa, J | 1 |
| Balakrishnan, B; Jayakrishnan, A; Labarre, D; Laurent, A; Payanam, U; Soman, D | 1 |
| Fujita, M; Horio, T; Ishihara, M; Ishizuka, T; Kanatani, Y; Kishimoto, S; Maehara, T; Morimoto, Y; Nakamura, S; Nogami, Y; Tanaka, Y | 1 |
| Lockhart, AS; Marr, R; Millner, R | 1 |
| He, C; Tang, C; Yin, C; Yin, L | 1 |
| Akaike, T; Arote, R; Cho, CS; Cho, MH; Choi, YJ; Jeong, HJ; Jiang, HL; Kim, EM; Kim, YK; Kwon, JT; Nah, JW | 1 |
1 review(s) available for chitosan and Liver Dysfunction
1 trial(s) available for chitosan and Liver Dysfunction
10 other study(ies) available for chitosan and Liver Dysfunction
| Article | Year |
|---|---|
Chitosan protects liver against ischemia-reperfusion injury via regulating Bcl-2/Bax, TNF-α and TGF-β expression.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Aspartate Aminotransferases; bcl-2-Associated X Protein; Caspase 3; Chitosan; Cytokines; Inflammation; Liver; Liver Diseases; Male; Malondialdehyde; Oxidative Stress; Protective Agents; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Wistar; Reactive Oxygen Species; Reperfusion Injury; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2020 |
Chitosan-stabilized selenium nanoparticles alleviate cardio-hepatic damage in type 2 diabetes mellitus model via regulation of caspase, Bax/Bcl-2, and Fas/FasL-pathway.
Topics: Animals; Antioxidants; bcl-2-Associated X Protein; Blood Glucose; Caspases; Chitosan; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Fas Ligand Protein; fas Receptor; Heart Diseases; Hypoglycemic Agents; Insulin Resistance; Liver; Liver Diseases; Male; Nanoparticles; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Selenium; Signal Transduction; Streptozocin | 2021 |
Microchannelled alkylated chitosan sponge to treat noncompressible hemorrhages and facilitate wound healing.
Topics: Alkylation; Animals; Bacterial Infections; Blood Coagulation; Chitosan; Hemorrhage; Hemostatic Techniques; Liver; Liver Diseases; Liver Regeneration; Male; Materials Testing; Microscopy, Electron, Scanning; Porosity; Rats; Surgical Sponges; Swine; Swine, Miniature; Wound Healing | 2021 |
GABA and 5-HT chitosan nanoparticles decrease striatal neuronal degeneration and motor deficits during liver injury.
Topics: Animals; Bromodeoxyuridine; Cell Differentiation; Cell Proliferation; Chitosan; Cytokines; Drug Delivery Systems; gamma-Aminobutyric Acid; Insulin-Like Growth Factor I; Liver; Liver Diseases; Male; Microscopy, Confocal; Motor Skills Disorders; Nanoparticles; Nerve Degeneration; Neuroglia; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Serotonin; Tumor Necrosis Factor-alpha | 2014 |
Increased cortical neuronal survival during liver injury: effect of gamma aminobutyric acid and 5-HT chitosan nanoparticles.
Topics: Animals; Cell Survival; Cerebral Cortex; Chitosan; Drug Therapy, Combination; gamma-Aminobutyric Acid; Liver Diseases; Male; Nanocapsules; Neurons; Neuroprotective Agents; Rats; Rats, Wistar; Reactive Oxygen Species; Serotonin; Treatment Outcome | 2014 |
A novel injectable tissue adhesive based on oxidized dextran and chitosan.
Topics: Adhesiveness; Animals; Chitosan; Dextrans; Injections; Liver Diseases; Male; Materials Testing; Oxidation-Reduction; Rabbits; Rats; Rats, Wistar; Tensile Strength; Tissue Adhesives; Treatment Outcome; Viscosity | 2017 |
Effect of photocrosslinkable chitosan hydrogel and its sponges to stop bleeding in a rat liver injury model.
Topics: Animals; Chitosan; Disease Models, Animal; Hemorrhage; Hemostatic Techniques; Hemostatics; Hydrogels; Liver; Liver Diseases; Male; Porifera; Rats; Rats, Sprague-Dawley | 2010 |
Chitosan arrests bleeding in major hepatic injuries with clotting dysfunction: an in vivo experimental study in a model of hepatic injury in the presence of moderate systemic heparinisation.
Topics: Animals; Bandages; Blood Coagulation Disorders; Chitosan; Disease Models, Animal; Female; Hemodynamics; Hemorrhage; Hemostatic Techniques; Hemostatics; Liver; Liver Diseases; Male; Sus scrofa; Treatment Outcome | 2010 |
Multifunctional polymeric nanoparticles for oral delivery of TNF-α siRNA to macrophages.
Topics: Acute Disease; Administration, Oral; Animals; Caco-2 Cells; Chitosan; Cysteine; Gene Silencing; Humans; Inflammation; Liver; Liver Diseases; Macrophages; Male; Mice; Mice, Inbred C57BL; Nanoconjugates; Nanoparticles; Polymers; RNA, Small Interfering; Tumor Necrosis Factor-alpha | 2013 |
Galactosylated chitosan-graft-polyethylenimine as a gene carrier for hepatocyte targeting.
Topics: Animals; Asialoglycoprotein Receptor; Cell Line; Chitosan; DNA; Female; Genetic Vectors; HeLa Cells; Hepatocytes; Humans; Injections, Intraperitoneal; Liver Diseases; Mice; Mice, Inbred BALB C; Nanoparticles; Polyethyleneimine; Targeted Gene Repair; Transfection | 2007 |